Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells

Oncogene

Volumn 34, Issue 22, 2015, Pages 2823-2835

  Watnick, R S ^a,b,c   Rodriguez, R K ^a,b,c   Wang, S ^a   Blois, A L ^a,d   Rangarajan, A ^c   Ince, T ^c   Weinberg, R A ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RHO FACTOR; THROMBOSPONDIN 1; E2F1 PROTEIN, HUMAN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM CELL; CELL ENGINEERING; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; FIBROBLAST; GENE INACTIVATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CELL; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; TRANSFORMED CELL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DOWN REGULATION; EPITHELIUM CELL; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

CELLS, CULTURED; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; RAS PROTEINS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84930083608     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.228     Document Type: Article

References (119)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-352.
4. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396: 84-88.
5. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela Arispe ML, Yeo TK et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999; 5: 1041-1056.
6. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995; 14: 351-362.
7. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220.
8. Ou YC, Chen JT, Yang CR, Horng YY, Kao YL, Cheng CL. Tumor angiogenesis and metastasis: correlation in invasive renal cell carcinoma. Zhonghua Yi Xue Za Zhi (Taipei) 1998; 61: 441-447.
9. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New Engl J Med 1991; 324: 1-8.
10. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S et al. Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer. Ann Surg Oncol 1998; 5: 585-589.
11. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-1397.
12. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996; 32A: 2386-2393.
13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
14. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [see comments]. Nat Med 1995; 1: 149-153.
15. Olive PL, Vikse C, Trotter MJ. Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe. Int J Radiat Oncol Biol Phys 1992; 22: 397-402.
16. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339-347.
17. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
18. Rogelj S, Weinberg RA, Fanning P, Klagsbrun M. Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 1988; 331: 173-175.
19. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 1999; 79: 427-438.
20. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003; 100: 12718-12723.
21. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990; 87: 3092-3096.
22. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.
23. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-662
24. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692.
25. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
26. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002; 295: 140-143.
27. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002; 1: 99-108.
28. Rodriguez Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98: 12485-12490.
29. Ribatti D, Alessandri G, Vacca A, Iurlaro M, Ponzoni M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer 1998; 77: 449-454.
30. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-717.
31. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 2005; 168: 643-653.
32. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15: 50-65.
33. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-1065.
34. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-rasdirected therapy. Mol Cancer Res 2005; 3: 413-423.
35. Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria Petit A, Filmus J et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000; 60: 490-498.
36. Udagawa T, Fernandez A, Achilles EG, Folkman J, D Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002; 16: 1361-1370.
37. Venkatesha S, Hanai J, Seth P, Karumanchi SA, Sukhatme VP. Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res 2006; 4: 821-829.
38. Castle V, Varani J, Fligiel S, Prochownik EV, Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991; 87: 1883-1888.
39. Burger P, Hilarius-Stokman P, de Korte D, van den Berg TK, van Bruggen R. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012; 119: 5512-5521.
40. Martin-Manso G, Galli S, Ridnour LA, Tsokos M, Wink DA, Roberts DD. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res 2008; 68: 7090-7099.
41. Li Y, Qi X, Tong X, Wang S. Thrombospondin 1 activates the macrophage Toll-like receptor 4 pathway. Cell Mol Immunol 2013; 10: 506-512.
42. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-2514.
43. Ngo CV, Gee M, Akhtar N, Yu D, Volpert O, Auerbach R et al. An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ 2000; 11: 4.
44. Tikhonenko AT, Black DJ, Linial ML. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem 1996; 271: 30741-30747.
45. Adhikary S, Peukert K, Karsunky H, Beuger V, Lutz W, Elsasser HP et al. Miz1 is required for early embryonic development during gastrulation. Mol Cell Biol 2003; 23: 7648-7657.
46. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 1994; 13: 4070-4079.
47. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983; 306: 194-196.
48. Seshadri R, Matthews C, Dobrovic A, Horsfall DJ. The significance of oncogene amplification in primary breast cancer. Int J Cancer 1989; 43: 270-272.
49. Trent J, Meltzer P, Rosenblum M, Harsh G, Kinzler K, Mashal R et al. Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc Natl Acad Sci USA 1986; 83: 470-473.
50. Gupta S, Seth A, Davis RJ. Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc Natl Acad Sci USA 1993; 90: 3216-3220.
51. Seth A, Alvarez E, Gupta S, Davis RJ. A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression. J Biol Chem 1991; 266: 23521-23524.
52. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995; 23: 1686-1690.
53. MacGregor D, Li LH, Ziff EB. Dominant negative mutants of Myc inhibit cooperation of both Myc and adenovirus serotype-5 E1a with Ras. J Cell Physiol 1996; 167: 95-105.
54. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 1999; 274: 32580-32587.
55. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994; 14: 5510-5522.
56. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell 1995; 80: 533-541.
57. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623-18632.
58. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
59. White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev 2003; 17: 1813-1816.
60. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81: 727-736.
61. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999; 96: 2110-2115.
62. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001; 20: 5826-5835.
63. Holsinger LJ, Spencer DM, Austin DJ, Schreiber SL, Crabtree GR. Signal transduction in T lymphocytes using a conditional allele of Sos. Proc Natl Acad Sci USA 1995; 92: 9810-9814.
64. Ren XD, Schwartz MA. Determination of GTP loading on Rho. Methods Enzymol 2000; 325: 264-272.
65. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995; 269: 1270-1272.
66. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992; 70: 401-410.
67. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996; 16: 5313-5327.
68. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M et al. Rhoassociated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996; 15: 2208-2216.
69. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994.
70. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol 1999; 9: 136-145.
71. Cardone RA, Bagorda A, Bellizzi A, Busco G, Guerra L, Paradiso A et al. Protein kinase A gating of a pseudopodial-located RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. Mol Biol Cell 2005; 16: 3117-3127.
72. He Z, Cho YY, Liu G, Ma WY, Bode AM, Dong Z. p38 Mitogen-activated protein kinase regulation of JB6 Cl41 cell transformation promoted by epidermal growth factor. J Biol Chem 2003; 278: 26435-26442.
73. Gould GW, Cuenda A, Thomson FJ, Cohen P. The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. Biochem J 1995; 311(Pt 3): 735-738.
74. Jallal B, Schlessinger J, Ullrich A. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells. J Biol Chem 1992; 267: 4357-4363.
75. Kozma SC, Bogaard ME, Buser K, Saurer SM, Bos JL, Groner B et al. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 1987; 15: 5963-5971.
76. Singhal RL, Yeh YA, Look KY, Sledge GW, Weber G. Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells. Life Sci 1994; 55: 1487-1492.
77. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987; 47(24 Pt 1): 6517-6521.
78. Rummukainen J, Kytola S, Karhu R, Farnebo F, Larsson C, Isola JJ. Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping. Cancer Genet Cytogenet 2001; 126: 1-7.
79. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400: 464-468.
80. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-4580.
81. Pipas JM, Levine AJ. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 2001; 11: 23-30.
82. Prives C, Beck Y, Gidoni D, Oren M, Shure H. DNA binding and sedimentation properties of SV40 T antigens synthesized in vivo and in vitro. Cold Spring Harb Symp Quant Biol 1980; 44(Pt 1): 123-130.
83. Rundell K, Parakati R. The role of the SV40 ST antigen in cell growth promotion and transformation. Semin Cancer Biol 2001; 11: 5-13.
84. Shenk TE, Berg P. Isolation and propagation of a segment of the simian virus 40 genome containing the origin of DNA replication. Proc Natl Acad Sci USA 1976; 73: 1513-1517.
85. Shenk TE, Carbon J, Berg P. Construction and analysis of viable deletion mutants of simian virus 40. J Virol 1976; 18: 664-671.
86. Volckaert G, Feunteun J, Crawford LV, Berg P, Fiers W. Nucleotide sequence deletions within the coding region for small-t antigen of simian virus 40. J Virol 1979; 30: 674-682.
87. Zerrahn J, Knippschild U, Winkler T, Deppert W. Independent expression of the transforming amino-terminal domain of SV40 large I antigen from an alternatively spliced third SV40 early mRNA. EMBO J 1993; 12: 4739-4746.
88. Beachy TM, Cole SL, Cavender JF, Tevethia MJ. Regions and activities of simian virus 40 T antigen that cooperate with an activated ras oncogene in transforming primary rat embryo fibroblasts. J Virol 2002; 76: 3145-3157.
89. Chao HH, Buchmann AM, DeCaprio JA. Loss of p19(ARF) eliminates the requirement for the pRB-binding motif in simian virus 40 large T antigenmediated transformation. Mol Cell Biol 2000; 20: 7624-7633.
90. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
91. Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 1991; 65: 1063-1072.
92. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053-1061.
93. Chittenden T, Livingston DM, Kaelin WG Jr. The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNAbinding protein. Cell 1991; 65: 1073-1082.
94. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 2004; 286: F278-F287.
95. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596-602.
96. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 2006; 26: 4240-4256.
97. Sauzeau V, Berenjeno IM, Citterio C, Bustelo XR. A transcriptional cross-talk between RhoA and c-Myc inhibits the RhoA/Rock-dependent cytoskeleton. Oncogene 2010; 29: 3781-3792.
98. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69: 8742-8751.
99. Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, Zhang X et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006; 281: 13957-13963.
100. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400: 468-472.
101. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57: 1735-1742.
102. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001; 98: 4622-4627.
103. Heighway J, Betticher DC, Hoban PR, Altermatt HJ, Cowen R. Coamplification in tumors of KRAS2, type 2 inositol 1, 4, 5 triphosphate receptor gene, and a novel human gene, KRAG. Genomics 1996; 35: 207-214.
104. Janocko LE, Lucke JF, Groft DW, Brown KA, Smith CA, Pollice AA et al. Assessing sequential oncogene amplification in human breast cancer. Cytometry 1995; 21: 18-22.
105. Galiana C, Lozano JC, Bancel B, Nakazawa H, Yamasaki H. High frequency of Kiras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog 1995; 14: 286-293.
106. Nagy A, Kozma L, Kiss I, Ember I, Takacs I, Hajdu J et al. Copy number of cancer genes predict tumor grade and survival of pancreatic cancer patients. Anticancer Res 2001; 21: 1321-1325.
107. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 1991; 11: 1107-1113.
108. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998; 95: 15587-15591.
109. Sepp-Lorenzino L, Rosen N, Lebwohl DE. Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. Cell Growth Differ 1994; 5: 1077-1083.
110. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R et al. A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 1994; 9: 1925-1929.
111. Weng LP, Smith WM, Dahia PL, Ziebold U, Gil E, Lees JA et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 1999; 59: 5808-5814.
112. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155: 1253-1260.
113. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet 1999; 8: 185-193.
114. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 1986; 83: 4834-4838.
115. Nau MM, Carney DN, Battey J, Johnson B, Little C, Gazdar A et al. Amplification, expression and rearrangement of c-myc and N-myc oncogenes in human lung cancer. Curr Top Microbiol Immunol 1984; 113: 172-177.
116. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535.
117. Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev 1993; 7: 1850-1861.
118. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
119. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406.